ANKS1A (Gene)

Synonyms:ANKS1, ANKS1A, ENTREZ:23294, HGNC:20961, MIM:608994, NM_015245, NP_056060, XM_005248964, XM_006715036, XM_011514431, XM_011514432, XM_011514433, XM_011514434, XM_011514435, XM_011514436, XM_011514437, XM_017010593, XM_024446383, XP_005249021, XP_006715099, XP_011512733, XP_011512734, XP_011512735, XP_011512736, XP_011512737, XP_011512738, XP_011512739, XP_016866082, XP_024302151, ankyrin repeat and sterile alpha motif domain containing 1A
Id:ENSG00000064999
Entrez:23294
Description:ankyrin repeat and sterile alpha motif domain containing 1A
Predicted to enable ephrin receptor binding activity. Predicted to be involved in ephrin receptor signaling pathway; neuron remodeling; and substrate-dependent cell migration. Predicted to act upstream of or within negative regulation of ubiquitin-dependent protein catabolic process and regulation of ephrin receptor signaling pathway. Located in cytosol and nucleoplasm. [provided by Alliance of Genome Resources, Apr 2022]

Analyze

Data Distillery
CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View ANKS1A's neighborhood in the knowledge graph.

Playbook Workflow Builder
Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with ANKS1A.

Gene Partnership Appyter
CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using ANKS1A.

Gene and Drug Landing Page Aggregator
GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for ANKS1A.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with ANKS1A.

Results found

Linked to

DISPLAY PER PAGE
This repository is under review for potential modification in compliance with Administration directives.